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Hemochromatosis is an autosomal recessive disorderwhich leads to abnormal iron deposition in the parenchyma ofmultiple organs
causing tissue damage. Accumulation of iron in the brain has been postulated to be associated with several neurodegenerative
diseases including Parkinson’s disease.The excess iron promotes Parkin and 𝛼-synuclein aggregation in the neurons. Excess iron has
also been noted in substantia nigra onMRI especially using susceptibility weighted imaging in patients with Parkinson’s disease.We
present a case of a young male with alleles for both C282Y and H63D who presented with signs of Parkinsonism and demonstrated
significant improvement with levodopa treatment.
1. Short Communication
Hemochromatosis is an autosomal recessive disorder [1]
which leads to abnormal iron deposition in the parenchyma
of multiple organs causing tissue damage. Though iron is
essential for several cellular functions including electron
transport chain, citric acid cycle, neurotransmitter synthesis,
andmyelogenesis [2], excess iron can cause damage to the tis-
sue by causing protein peroxidation, lipid peroxidation, and
DNA oxidation via free radical damage. This can eventually
lead to cellular and neuronal damage or death [3, 4].The gene
responsible for hemochromatosis is the HFE within Human
Leukocyte Antigen (HLA) class I region on chromosome 6.
HFE is a ligand for TfR [5]. Interaction between TfR and
HFE leads to decreased affinity with which the receptor binds
transferrin and this interaction may also modulate iron entry
into the cell. When a mutant or nonfunctional variant of the
HFE gene is present, ferritin levels are not under influence of
a normal and functional HFE gene, which leads to enhanced
accumulation of iron in peripheral tissues. In the brain, HFE
is expressed in the choroid epithelial cells, endothelial cells in
the microvasculature, and ependymal cell lining within the
brain where it can affect iron accumulation in the brain [6, 7].
Accumulation of iron in the brain has been postulated to be
associated with several neurodegenerative diseases including
Parkinson’s disease [8]. The excess iron promotes Parkin and
𝛼-synuclein aggregation in the neurons [8–10]. Excess iron
has also been noted in substantia nigra on MRI especially
using susceptibility weighted imaging (SWI) in patients with
Parkinson’s disease [10]. Substantia nigra is more vulnera-
ble to excessive iron accumulation than other surrounding
regions. Increased iron in the substantia nigra is associated
with ineffective handling of reactive oxygen species and,
therefore, oxidative stress. Excess iron can further lead to
direct injury to the mitochondria [11]. A brief literature
review using the terms “hemochromatosis” and “Parkinson’s
disease” revealed that only 5 cases of concomitant Parkinson’s
disease and hemochromatosis have been reported before [12,
13].The largest case series among them consisted of four cases
with preexisting hemochromatosis, developing idiopathic
Parkinson’s disease between the ages of 55 and 63 years [12].
Three out of the four cases described in this series had C282Y
homozygous mutations.
We present the case of a 41-year-old right handed Cau-
casian male who came to our clinic with a six-month history
of bilateral hand rest and action tremor, more pronounced
on the right. Further inquiry revealed associated symptoms
including anosmia, shoulder stiffness, difficulty rising up
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Figure 1: DaTscan shows asymmetric radiotracer uptake with
mildly decreased uptake in the right putamen.
from a seated position, depressedmood, and fatigue. His past
medical historywas notable for hemochromatosis,migraines,
restless leg syndrome, and obstructive sleep apnea. He has
compound heterozygosity for the genetic hemochromatosis
gene in that he has alleles for both C282Y and H63D. Family
history was significant for Parkinson’s disease in his mother,
which first manifested when she was around 50 years of age.
His neurological exam demonstrated normal higher
mental function, flat affect, masked-facies, normal cranial
nerves, moderate rigidity in right arm, mild rigidity in left
arm, bilateral bradykinesia on repetitive finger tapping, and
mixed resting and action tremors in the right and left hand.
The remainder of motor, sensory, and cerebellar exam was
unremarkable. His gait was narrow-based with normal stride
but diminished right arm swing. A levodopa challenge with
sequential escalation of doses led to mild improvement in his
appendicular symptoms.
A brain MRI was done which was unremarkable whereas
single-photon emission computed tomography (SPECT) brain
imaging with I-123 ioflupane (“DaTscan”) revealed asymmet-
ric radiotracer uptake with mildly decreased uptake in the
right putamen [Figure 1].
Over the following eightmonths the patient showedmod-
est but clear improvement in symptoms on treatment with
oral carbidopa-levodopa 25–100mg slowly escalated to three
tablets four times a day.
Apart from our case, only one other case describes an
onset of Parkinsonian symptomatology at a young age [13],
thereby contributing to the literature on this controversial
topic.
Given the theoretical risk of increased Parkinsonism in
patients with disorders of iron regulation, several population
based studies have been done to determine the association
between hemochromatosis and its genetic mutations with
Parkinson’s disease but the results have been conflicting. One
Norwegian and two Italian studies failed to find any signif-
icant association between the frequencies of C282Y, H63D,
and S65Cmutations in Parkinson’s disease group and control
group [14–16]. A Dutch study observed increased risk of
Parkinson’s disease in patients with C282Y gene muta-
tion [17]. A Portuguese population based study also noted
increased frequency of C282Y carrier status in Parkinson’s
disease cohort [18]. An Australian study however observed
that C282Y allele could be protective against Parkinson’s
disease [19], contrary to the priorly mentioned Dutch and
the Portuguese studies. Among these studies, only one study
by Biasiotto et al. [16] looked at the age of onset between
Parkinson’s disease patients with noHFEmutations or at least
onemutation associatedwith hemochromatosis.They did not
find any significant difference between the age of onset among
other factors such as clinical presentation and response to
levodopa. They concluded that, in the Italian population, the
most common HFE mutations have no specific influence on
the clinical features of the disease and are not associated with
a higher risk of developing the disease.
While there exists a plausible risk of neurodegenerative
disease related to aberrant iron metabolism, several popu-
lation based studies have failed to ascertain a more definite
association between HFE gene mutations in Parkinson’s
disease populations.
The interplay between certain environmental and genetic
factors may predispose certain patients suffering from
hemochromatosis to develop Parkinson’s disease at a younger
age. Based on the data discussed above, future directions
should include analyzing HFE mutation frequencies in
patients with early onset Parkinsonism to gather more evi-
dence towards this hypothesis.
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